Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Adaptimmune Therapeutics PLC
Accounts Payable
Adaptimmune Therapeutics PLC
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Accounts Payable
$9.4m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Accounts Payable
$9.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Accounts Payable
£24.4m
|
CAGR 3-Years
28%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Accounts Payable
$15.2m
|
CAGR 3-Years
47%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Accounts Payable
£19.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-9%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Accounts Payable
£49.6m
|
CAGR 3-Years
54%
|
CAGR 5-Years
45%
|
CAGR 10-Years
30%
|
|
Adaptimmune Therapeutics PLC
Glance View
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 494 full-time employees. The company went IPO on 2015-05-06. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.
See Also
What is Adaptimmune Therapeutics PLC's Accounts Payable?
Accounts Payable
9.4m
USD
Based on the financial report for Jun 30, 2025, Adaptimmune Therapeutics PLC's Accounts Payable amounts to 9.4m USD.
What is Adaptimmune Therapeutics PLC's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
1%
Over the last year, the Accounts Payable growth was 25%. The average annual Accounts Payable growth rates for Adaptimmune Therapeutics PLC have been -16% over the past three years , 1% over the past five years .
